BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10622225)

  • 1. New developments in the treatment of acute myeloid leukemia: focus on topotecan.
    Kantarjian H
    Semin Hematol; 1999 Oct; 36(4 Suppl 8):16-25. PubMed ID: 10622225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of apoptosis by topotecan: implications for the treatment of leukemia.
    Seiter K
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):22-5. PubMed ID: 9779878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M
    Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New chemotherapeutic agents in acute myeloid leukemia.
    Kantarjian HM; Estey EH; Keating MA
    Leukemia; 1996 Apr; 10 Suppl 1():S4-6. PubMed ID: 8618470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
    Oriol A; Ribera JM; Esteve J; Guàrdia R; Brunet S; Bueno J; Pedro C; Llorente A; Tormo M; Besalduch J; Sánchez JM; Batlle M; Vivancos P; Carreras E; Vilà JM; Julià A; Sierra J; Montserrat E; Feliu E;
    Haematologica; 2004 Jul; 89(7):791-800. PubMed ID: 15257930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
    Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acute myeloid leukemia].
    Miyazaki Y; Kuriyama K
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1192-8. PubMed ID: 11579629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of childhood acute myeloid leukemia.
    ter Bals E; Kaspers GJ
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):917-29. PubMed ID: 16221060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acute myeloid leukemia in older patients.
    Roboz GJ
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):285-95. PubMed ID: 17338649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents in acute myeloid leukemia.
    Aribi A; Ravandi F; Giles F
    Cancer J; 2006; 12(2):77-91. PubMed ID: 16630396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
    Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
    Thomas X; Elhamri M; Chelghoum Y; Reman O; Arnaud P; Raffoux E; Le QH; Tavernier E; Dombret H; Michallet M
    Ann Hematol; 2005 Jun; 84(6):376-82. PubMed ID: 15782343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
    McCluskey AG; Boyd M; Gaze MN; Mairs RJ
    Cancer Lett; 2005 Oct; 228(1-2):221-7. PubMed ID: 15935554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia.
    Fiegl M; Zimmermann I; Lorenz I; Hiddemann W; Braess J
    Ann Hematol; 2008 Jan; 87(1):27-33. PubMed ID: 17710400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S; Gomez SP; McCarley D; Mainwaring MG
    Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.